mRNA Cancer Vaccines Have Proven 5-Year Efficacy Data: Regulatory Submissions in 2026

mRNA cancer vaccines Phase 3 clinical data and regulatory submission timeline

Five years of follow-up on mRNA cancer vaccines. The same hazard ratio as year three. That is the signal that matters most in the latest data from the Moderna/Merck personalized mRNA cancer vaccine program — not because the number is exceptional, but because it has not moved. A benefit that holds its magnitude over five … Read more